Table 1 Characteristics of 150 trial start-ups for the 16 multi-centre trials evaluated
Number of start-ups (n = 150) | Frequency | |
|---|---|---|
Phase | ||
1 | 17 | 11% |
2 | 27 | 18% |
3 | 98 | 65% |
4 | 8 | 5% |
Disease area of trial | ||
Nephrology | 54 | 36% |
Oncology | 40 | 27% |
Endocrinology | 24 | 16% |
Neurology | 22 | 15% |
Paediatrics | 10 | 7% |
Country | ||
Australia | 126 | 84% |
South Korea | 10 | 7% |
Hong Kong SAR | 5 | 3% |
Taiwan | 5 | 3% |
New Zealand | 4 | 3% |
Trial site ownership | ||
Government | 108 | 72% |
Private | 18 | 12% |
Unknown | 24 | 16% |
Scope guidelines for the ethics review | ||
Yes | 116 | 77% |
No | 34 | 23% |
Mutual acceptance of other ethics committee approval | ||
Yes | 79 | 53% |
No | 55 | 37% |
Unknown | 16 | 11% |
Applications triaged low/medium/high risk for ethics review | ||
Yes | 96 | 64% |
No | 49 | 33% |
Unknown | 5 | 3% |
Scope guidelines used for the governance review | ||
Yes | 112 | 75% |
No | 38 | 25% |
Applications triaged low/medium/high risk for governance review | ||
Yes | 111 | 74% |
No | 31 | 21% |
Unknown | 8 | 5% |
COVID-19 pandemic | ||
Pre-pandemic (Jan 2014–Dec 2019) | 114 | 76% |
During or after pandemic (Jan 2020–Dec 2022) | 36 | 24% |